Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | FRalphaDC vaccine |
Synonyms | |
Therapy Description |
FRalphaDC vaccine comprises autologous dendritic cells loaded with multi-epitope peptides derived from FOLR1 (FRalpha), which may induce an immune response against FOLR1-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FRalphaDC vaccine | FRaDC vaccine|Multi-epitope folate receptor alpha-loaded dendritic cell vaccine | FOLR1-targeted Therapy 24 | FRalphaDC vaccine comprises autologous dendritic cells loaded with multi-epitope peptides derived from FOLR1 (FRalpha), which may induce an immune response against FOLR1-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06639074 | Phase II | FRalphaDC vaccine | Folate Receptor Alpha Dendritic Cells (FRaDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial | Recruiting | USA | 0 |